Use of an in vivo FTA assay to assess the magnitude, functional avidity and epitope variant cross-reactivity of T cell responses following HIV-1 recombinant poxvirus vaccination

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Wijesundara, Danushka K ^a   Ranasinghe, Charani ^a   Jackson, Ronald J ^a   Lidbury, Brett A ^b   Parish, Christopher R ^b   Quah, Benjamin J C ^b  

^a Biology and Environment   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POL PROTEIN; POXVIRUS VECTOR; VIRUS ENVELOPE PROTEIN; DNA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FLUORESCENCE ANALYSIS; FLUORESCENT TARGET ARRAY ASSAY; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ANIMAL; BAGG ALBINO MOUSE; FLUORESCENCE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGY; MICROARRAY ANALYSIS; POXVIRIDAE; POXVIRIDAE INFECTIONS; PROCEDURES; VACCINATION; VACCINIA VIRUS;

AIDS VACCINES; ANIMALS; CROSS REACTIONS; EPITOPES; FLUORESCENCE; HIGH-THROUGHPUT SCREENING ASSAYS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; MALE; MICE; MICE, INBRED BALB C; MICROARRAY ANALYSIS; POXVIRIDAE; POXVIRIDAE INFECTIONS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, DNA; VACCINIA VIRUS;

EID: 84907536539     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105366     Document Type: Article

References (31)

1. Kelleher AD, Puls RL, Bebbington M, Boyle D, Ffrench R, et al. (2006) A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 20: 294-297.
2. Hemachandra A, Puls RL, Sirivichayakul S, Kerr S, Thantiworasit P, et al. (2010) An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Human vaccines 6: 835-840.
3. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
4. Cohen J (2013) AIDS research. More woes for struggling HIV vaccine field. Science 340: 667.
5. Berger CT, Frahm N, Price DA, Mothe B, Ghebremichael M, et al. (2011) High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. Journal of virology 85: 9334-9345.
6. Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, et al. (2009) Antigen sensitivity is a major determinant of CD8 + T-cell polyfunctionality and HIV-suppressive activity. Blood 113: 6351-6360.
7. Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, et al. (2012) CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PloS one 7: e29717.
8. Barchet W, Oehen S, Klenerman P, Wodarz D, Bocharov G, et al. (2000) Direct quantitation of rapid elimination of viral antigen-positive lymphocytes by antiviral CD8(+) T cells in vivo. European journal of immunology 30: 1356-1363. (Pubitemid 30311965)
9. Regoes RR, Barber DL, Ahmed R, Antia R (2007) Estimation of the rate of killing by cytotoxic T lymphocytes in vivo. Proc Natl Acad Sci U S A 104: 1599-1603. (Pubitemid 46214636)
10. Yates A, Graw F, Barber DL, Ahmed R, Regoes RR, et al. (2007) Revisiting estimates of CTL killing rates in vivo. PLoS One 2: e1301.
11. Quah BJ, Parish CR (2012) New and improved methods for measuring lymphocyte proliferation in vitro and in vivo using CFSE-like fluorescent dyes. Journal of immunological methods 379: 1-14.
12. Quah BJ, Wijesundara DK, Ranasinghe C, Parish CR (2013) Fluorescent target array T helper assay: a multiplex flow cytometry assay to measure antigen-specific CD4+ T cell-mediated B cell help in vivo. Journal of immunological methods 387: 181-190.
13. Ranasinghe C, Eyers F, Stambas J, Boyle DB, Ramshaw IA, et al. (2011) A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations. Vaccine 29: 3008-3020.
14. Ranasinghe C, Medveczky JC, Woltring D, Gao K, Thomson S, et al. (2006) Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine 24: 5881-5895. (Pubitemid 44173003)
15. Ranasinghe C, Turner SJ, McArthur C, Sutherland DB, Kim JH, et al. (2007) Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. Journal of immunology 178: 2370-2379. (Pubitemid 46233436)
16. Ranasinghe C, Trivedi S, Stambas J, Jackson RJ (2013) Unique IL-13Ralpha2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity. Mucosal immunology.
17. Oehen S, Brduscha-Riem K, Oxenius A, Odermatt B (1997) A simple method for evaluating the rejection of grafted spleen cells by flow cytometry and tracing adoptively transferred cells by light microscopy. Journal of immunological methods 207: 33-42. (Pubitemid 27400470)
18. Yerly D, Heckerman D, Allen TM, Chisholm JV 3rd, Faircloth K, et al. (2008) Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. Journal of virology 82: 3147-3153. (Pubitemid 351329204)
19. Woodland DL (2004) Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 25: 98-104.
20. Estcourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveckzy CJ, et al. (2002) Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int Immunol 14: 31-37. (Pubitemid 34083395)
21. Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Berzofsky JA (2007) A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. Journal of immunology 178: 7211-7221. (Pubitemid 46847447)
22. Belyakov IM, Ahlers JD, Nabel GJ, Moss B, Berzofsky JA (2008) Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology 381: 106-115.
23. Reece JC, Loh L, Alcantara S, Fernandez CS, Stambas J, et al. (2010) Timing of immune escape linked to success or failure of vaccination. PLoS One 5(9). e12774.
24. Mata M, Paterson Y (1999) Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. Journal of immunology 163: 1449-1456. (Pubitemid 29352766)
25. Earl PL, Cotter C, Moss B, VanCott T, Currier J, et al. (2009) Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 27: 5885-5895.
26. Wild J, Bieler K, Kostler J, Frachette MJ, Jeffs S, et al. (2009) Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral immunology 22: 309-319.
27. Takeshita T, Takahashi H, Kozlowski S, Ahlers JD, Pendleton CD, et al. (1995) Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule. Journal of immunology 154: 1973-1986.
28. Quah BJ, Wijesundara DK, Ranasinghe C, Parish CR (2012) Fluorescent target array killing assay: A multiplex cytotoxic T-cell assay to measure detailed T-cell antigen specificity and avidity in vivo. Cytometry Part A: the journal of the International Society for Analytical Cytology 81: 679-690.
29. Coupar BE, Purcell DF, Thomson SA, Ramshaw IA, Kent SJ, et al. (2006) Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine 24: 1378-1388. (Pubitemid 43222047)
30. Quah BJ, Parish CR (2010) The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte proliferation. Journal of visualized experiments: JoVE.
31. Quah B, Ni K, O'Neill HC (2004) In vitro hematopoiesis produces a distinct class of immature dendritic cells from spleen progenitors with limited T cell stimulation capacity. Int Immunol 16: 567-577. (Pubitemid 38489431)